Hikma Pharmaceuticals Stock Forecast, Price & News

0.00 (0.00 %)
(As of 04/9/2021 12:00 AM ET)
Today's Range
Now: $59.68
50-Day Range
MA: $61.50
52-Week Range
Now: $59.68
Average Volume423 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops, manufactures, and sells oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, anesthetic, sedative, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Hikma Pharmaceuticals logo

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable


MGE Energy Issues December 2020 'Interim Report'
December 15, 2020 |  finance.yahoo.com
MGE Energy Issues Third-Quarter Financial Update
November 6, 2020 |  finance.yahoo.com
Hikma Pharmaceuticals Plc ADR (HKMPY)
October 20, 2020 |  nasdaq.com
Who Has Been Buying MGE Energy, Inc. (NASDAQ:MGEE) Shares?
October 16, 2020 |  finance.yahoo.com
We're Watching These Trends At MGE Energy (NASDAQ:MGEE)
August 26, 2020 |  finance.yahoo.com
Hikma Pharmaceuticals Regulatory News
August 9, 2020 |  lse.co.uk
MGE Energy Reports Second-Quarter Earnings
August 6, 2020 |  finance.yahoo.com
FDA Approves First Generic Version Of Vascepa; Amarin On Watch
May 23, 2020 |  markets.businessinsider.com
Amarin Down 10% in Pre-Market On Generic Approval
May 22, 2020 |  finance.yahoo.com
See More Headlines


Overall MarketRank

0.44 out of 5 stars

Medical Sector

1693rd out of 2,016 stocks

Drug Manufacturers - Specialty & Generic Industry

55th out of 61 stocks

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
0.00 (0.00 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HKMPY News and Ratings via Email

Sign-up to receive the latest news and ratings for HKMPY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Hikma Pharmaceuticals (OTCMKTS:HKMPY) Frequently Asked Questions

What stocks does MarketBeat like better than Hikma Pharmaceuticals?

Wall Street analysts have given Hikma Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Hikma Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How has Hikma Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Hikma Pharmaceuticals' stock was trading at $48.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HKMPY shares have increased by 24.3% and is now trading at $59.68.
View which stocks have been most impacted by COVID-19

Who are Hikma Pharmaceuticals' key executives?

Hikma Pharmaceuticals' management team includes the following people:
  • Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 64, Pay $3.01M)
  • Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 52, Pay $3.72M)
  • Mr. Mazen Samih Taleb Darwazah, Exec. Vice Chairman & Pres of MENA (Age 63, Pay $2.16M)
  • Mr. Khalid Waleed Hosny Al Nabilsi, Chief Financial Officer (Age 49)
  • Dr. Shahin Fesharaki, Chief Scientific Officer & Global Head of Research Devel.
  • Mr. Hussein Arkhagha, Chief Counsel
  • Mr. Bassam Wael Rushdi Kanaan, Exec. VP of Corp. Devel. and M&A (Age 56)
  • Ms. Susan Ringdal, Exec. VP of Strategic Planning & Global Affairs
  • Ms. Majda Labadi, Exec. VP of Organisational Devel.
  • Mr. Riad Mishlawi, Pres of Injectables

Who are some of Hikma Pharmaceuticals' key competitors?

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the OTCMKTS under the ticker symbol "HKMPY."

How do I buy shares of Hikma Pharmaceuticals?

Shares of HKMPY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hikma Pharmaceuticals' stock price today?

One share of HKMPY stock can currently be purchased for approximately $59.68.

How many employees does Hikma Pharmaceuticals have?

Hikma Pharmaceuticals employs 8,600 workers across the globe.

What is Hikma Pharmaceuticals' official website?

The official website for Hikma Pharmaceuticals is www.hikma.com.

Where are Hikma Pharmaceuticals' headquarters?

Hikma Pharmaceuticals is headquartered at 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company can be reached via phone at +44-20-73992760.

This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.